Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis
Liver International 41(8):1853-1866, 2021
A genetic map of the mouse dorsal vagal complex and its role in obesity
Nature Metabolism 3(4):530-545, 2021
Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis
Nature Metabolism 2(5):413–431, 2020
Incretin combination therapy for the treatment of non-alcoholic steatohepatitis
Diabetes, Obesity and Metabolism 22(8):1328-1338, 2020
Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH
BMC Gastroenterology 19(1):228, 2019
Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
Scientific Reports 9(1):15582, 2019
Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice
Physiology and Behavior 192:72-81, 2018